SAFE vs Priced Round

At pre-seed and most seeds, a post-money SAFE is the right instrument. A priced round is for when a lead wants a board seat and a price, and you want that lead enough to take the extra time. The instrument is not a philosophy. It is a trade between speed and structure.

Founders lose months arguing about which is "more founder friendly." The founder-friendly move is the one that closes cleanly, on standard paper, with people you would take a call from in two years.

What a SAFE actually is

A SAFE (Simple Agreement for Future Equity) is a contract that converts into shares at a future priced round. You are not selling stock today. You are selling the right to buy stock later, usually at a discount to the next round's price, subject to a valuation cap.

The Y Combinator post-money SAFE is the default in 2026. "Post-money" means the cap already includes the SAFE itself, so you can calculate dilution the day you sign. The older pre-money SAFE made that math fuzzy. Do not use it unless a lawyer has a specific reason.

A valuation cap is not your valuation. It is the worst price the investor will pay at conversion. If you raise a Series A at a $40M pre-money and your SAFE cap was $12M, the SAFE holder converts as if the company were worth $12M. That is the deal. Say it that way in the meeting.

A discount without a cap is a gift to the next round and a problem for you. A cap without a discount is normal. An uncapped SAFE with a discount is how you surprise yourself on the cap table.

When a priced round is worth it

Price the round when at least two of these are true:

• A lead is writing a check large enough to care about a board seat and pro-rata (typically $1.5M or more at seed, or any Series A)
• You have enough metrics that a price is defensible rather than invented
• You want the governance that comes with it: a real board, information rights that go both ways, a clean reset of the option pool

A priced seed takes longer. There is a term sheet, a full set of NVCA-style documents, and diligence that a SAFE mostly skips. Budget three to five extra weeks and legal fees on both sides. That cost is justified when the lead is someone you actually want on the board. It is not justified because a blog said priced rounds are more "serious."

Most pre-seeds should never be priced. Many seeds should stay on a SAFE, especially a party round of angels and one seed fund. Series A is almost always priced.

Dilution you can explain on a napkin

Work an example out loud before the first meeting. Suppose you raise $2M on a $10M post-money SAFE. The SAFE holders own 20% at conversion, before the Series A. Your option pool and the A itself dilute you further. If you then raise a $8M Series A at a $32M pre-money with a 10% post-money option pool shuffle, founder ownership drops again, hard.

The exact numbers depend on the term sheet. The point is to know the shape:

Convertible notes still show up. They accrue interest and they have a maturity date, which means they can become a negotiation later if you have not priced. Prefer a SAFE unless the investor cannot sign one (some family offices and non-US vehicles).

Terms that matter on a SAFE

Most SAFEs should be vanilla. The ones that are not vanilla are where founders get hurt.

• One cap, one form. The standard YC post-money SAFE. Side letters for everyone is how you create a second raise inside the first.
• MFN (most favored nation). If you later issue a SAFE with a lower cap or a better discount, earlier signers get those terms. Harmless in a short rolling close. Poisonous if you keep issuing paper for a year.
• Pro-rata. The right to invest in the next round to keep their percent. Reasonable for a lead or a large check. Do not give it to every $25K angel. Super pro-rata (the right to increase their percent) is a Series A problem wearing a seed costume.
• Information rights. A short monthly or quarterly update is fine. A seat at every board-equivalent discussion for a $50K check is not.
• Side letters that look like control. Approval rights over hiring, fundraising, or a sale, attached to a SAFE, are priced-round terms without priced-round money. Decline them.

If an investor will only do a SAFE with a board observer seat, a 2x cap-adjusted preference, or a veto on the next raise, they are not doing a SAFE. They are doing a priced round they do not want to document. Walk or price it properly.

How to talk about the number

State the cap and the reasoning in one sentence. "We are raising $2.5M on a $12M post-money SAFE. That is in line with seed rounds in this category at our traction, and it leaves room for the A to be a step-up rather than a flat."

Do not apologize. Do not negotiate the cap in the first meeting. If they push on price before they have shown interest in the business, that is information about them. The objection playbook covers the rest of that conversation.

A cap you cannot grow into is a future down round. A cap so low that the SAFE owns 35% before the A is a future hiring and morale problem. Pick a number a Series A partner can look at without wincing.

Failure modes

1. Stacking custom SAFEs. Four caps, two discounts, one MFN, three side letters. Your Series A counsel will make you clean this up on your dime.
2. Treating the cap as the company's valuation in public. It is not. Calling a $15M cap "our $15M valuation" trains the next investor to argue with a number you do not have.
3. Pricing a pre-seed. You will spend the runway on lawyers and a board before you have a product.
4. An uncapped note "to keep it simple." Simple until conversion day.
5. Giving pro-rata to the whole cap table. Your A lead will not have room.
6. Using a priced round to feel legitimate. Legitimacy is customers and a clean story. Paper is just paper.